Our findings did not show statistically significant differences between luminal A and B tumors, in relation to the expression of CD200R on non-hematopoietic cells, suggesting that CD200/CD200R-mediated immune suppression may not be a dominant mechanism in the breast cancer subtypes under study. This evidence concerns the gene CD200 and breast cancer.